Rigel Pharmaceuticals (RIGL) Change in Account Payables (2010 - 2026)

Rigel Pharmaceuticals' Change in Account Payables history runs 17 years deep, the most recent figure standing at -$2.7 million for Q1 2026.

• On a quarterly basis, Change in Account Payables fell 539.84% year-over-year to -$2.7 million in Q1 2026; TTM through Mar 2026 was $532000.0, a 110.0% increase from a year earlier, with the FY2025 full-year figure at $3.9 million, up 201.29% from the prior year.
• Change in Account Payables retreated to -$2.7 million in Q1 2026 per RIGL's latest filing, from $3.3 million in the prior quarter.
• Across five years, Change in Account Payables topped out at $4.8 million in Q4 2022 and bottomed at -$3.4 million in Q3 2025.
• The 5-year median for Change in Account Payables is -$476000.0 (2024), against an average of $45058.8.
• Across the five-year window, Change in Account Payables surged 802.73% in 2025 and sank 539.84% in 2026, its largest moves.
• Year by year, Change in Account Payables stood at $4.8 million in 2022, then slumped by 117.9% to -$857000.0 in 2023, then soared by 44.46% to -$476000.0 in 2024, then jumped by 802.73% to $3.3 million in 2025, then tumbled by 180.87% to -$2.7 million in 2026.
• Per Business Quant, the three latest RIGL Change in Account Payables figures stand at -$2.7 million (Q1 2026), $3.3 million (Q4 2025), and -$3.4 million (Q3 2025).